Dr. Reddy's : R&D coffer - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Dr. Reddy's : R&D coffer

May 30, 2001

Dr. Reddy’s has announced out-licensing of its diabetes molecule (DRF 4158) to Novartis. As per the terms of the agreement, Dr. Reddy would receive US$ 55 m in up front and milestone earnings. This is almost more than double its expected earnings for FY01. This milestone payment would be received prior to commercial launch of the molecule. While Novartis would have exclusive rights for worldwide development and commercialization, Dr. Reddy would have co-promotion rights for India. The company has been licensing its molecules to multinational companies for further development after conducting pre clinical studies, as part of its strategy to finance huge clinical trial costs. The company has already licensed two molecules (DRF-2725 and DRF 2593) in the anti-diabetes area to Novo Nordisk, a world leader in diabetic segment. The out-licensing has already earned the company, US$ 8 m till date. The huge milestone payment for the third molecule of US$ 55 m (Rs 2.6 bn approx.) is reflective of the company’s strength in pharma R&D. This is the largest ever milestone payment received by any pharma company in India.

Dr. Reddy’s strong research pipeline can be summarized as under.

Dr. Reddy’s R&D Coffer
Molecule Name Therapeutic
segment
Remarks
DRF 2593 Diabetes Licensed to Novo Nordisk.
Currently in Phase II of clinical trials
DRF 2725 Diabetes Licensed to Novo Nordisk.
Currently in Phase II of clinical trial in several
regulated markets including US and Europe.
Worldwide launch expected in 2004-05
DRF 4158 Diabetes Licensed to Novartis.
Pre-clinical already completed.
DRF NPPC Diabetes Pre-clinical completed.
Exploring licensing prospects.
DRF 1042 Cancer Phase I Clinical trial
DRF 1644 Cancer Currently, in pre-clinical studies
DRF ACXX Cancer Currently, in pre-clinical studies
DRF 4848 Pain Management Pre-clinical studies
DRF 4832 Cardiovascular Clinical trial contract given to
Simbec Research, UK

Further, proceeds from recently completed ADR are expected to be utilized for R&D activities. This would further strength the company’s pipeline. The company is expected to announce its consolidated results (with Cheminor drugs) on May 31, 2001. We expect the company to post an EPS of Rs 34.8, on a consolidated basis. Apart from the current windfall income and other positive news flow expected from its research pipeline, clear visibility of earnings from the US generic market is likely to create a positive impact on the stock price. At Rs 1,400, the stock trades at 40.2 and 33 times FY01 and FY02 expected earnings respectively (without taking into account extraordinary incomes like gains from US generic market and milestone payments).


Equitymaster requests your view! Post a comment on "Dr. Reddy's : R&D coffer". Click here!

  

More Views on News

DR. REDDYS LAB Announces Quarterly Results (3QFY19); Net Profit Up 67.0% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 67.0% YoY). Sales on the other hand came in at Rs 39 bn (up 0.8% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

More Views on News

Most Popular

How the 8-Year Cycle Can Help Identify Multibaggers (Fast Profits Daily)

Sep 11, 2020

This is how you can apply the greed and fear cycle in the market to pick stocks.

Why am I Recommending Caution? (Fast Profits Daily)

Sep 9, 2020

This is why I have changed my short-term view on the market.

Why We Picked This Small-cap Stock for Our Hidden Treasure Subscribers (Profit Hunter)

Sep 17, 2020

This leading household brand will profit big time in a post covid world.

This Could Be the Best September for Auto Stocks (Profit Hunter)

Sep 11, 2020

Here's why I think this month could be a great for auto stocks.

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Sep 22, 2020 03:37 PM

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB - CADILA HEALTHCARE COMPARISON

COMPARE DR. REDDYS LAB WITH

MARKET STATS